Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07824843) titled 'Safety Study of GMDTC Injection in Participants With Solid Tumors and Cisplatin-Induced Renal Dysfunction' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Guangdong Jianersheng Pharmaceutical Technology Co., Ltd.
Condition:
Cisplatin Nephrotoxicity
Cisplatin Adverse Reaction
Intervention:
Drug: GMDTC 1 mg/ml
Drug: GMDTC 2mg/ml
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: October 2026
Target Sample Size: 60
Countries of Recruitment:
C...